 |
December 2, 2019 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Read
December 2, 2019 - Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries
Read
November 6, 2019 - Puma Biotechnology Reports Third Quarter 2019 Financial Results
Read
November 5, 2019 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Read
November 4, 2019 - Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
Read
October 23, 2019 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read
October 2, 2019 - FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read
September 25, 2019 - Puma Biotechnology to Present at Cantor Global Healthcare Conference
Read
September 11, 2019 - Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read
September 4, 2019 - Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer
Read
September 3, 2019 - FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases
Read
September 3, 2019 - Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Read
August 8, 2019 - Puma Biotechnology Reports Second Quarter 2019 Financial Results
Read
July 24, 2019 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read
July 16, 2019 - Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
Read
July 3, 2019 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
Read
July 1, 2019 - Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read
June 4, 2019 - Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2 Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Read
June 2, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Read
May 29, 2019 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference
Read
May 9, 2019 - Puma Biotechnology Reports First Quarter 2019 Financial Results
Read
May 8, 2019 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019
Read
|
|
Upcoming Events
Dec. 10, 2019 - San Antonio Breast Cancer Symposium
More
Past Events
Nov. 12, 2019 - Credit Suisse 28th Annual Healthcare Conference
More
Nov. 6, 2019 - Puma Biotechnology 3Q-2019 Financial Results Conference Call
More
October 3, 2019 - Cantor Global Healthcare Conference
More
September 10, 2019 - H.C. Wainwright 21st Annual Global Investment Conference
More
September 5, 2019 - Citi’s 14th Annual Biotech Conference
More
August 8, 2019 - Puma Biotechnology 2Q-2019 Financial Results Conference Call
More
|
Annual Report Archives
Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
Medical Inquiries:
1-844-MED-PUMA (1-844-633-7862), or
medinfo@pumabiotechnology.com
Business Development:
info@pumabiotechnology.com
Investor Relations:
ir@pumabiotechnology.com
|
